When you need to whip up a quick sandwich or just have a fun and delicious way to sneak some extra protein into your diet, nothing hits the spot like some peanut butter. Everyone has come to love this spread, and we have found it goes great in dips, on top of desserts, and even makes its way into a ton of recipes thanks to its ease to cook with Continue reading →

Global high blood pressure treatment market is set to witness a substantial CAGR in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. The increased market growth can be identified by increasing number of hypertension patients. Continue reading →

Cardiovascular diseases (CVDs) have emerged to be the leading cause of death globally, claiming an estimated 17.9 million lives almost every year of which, about 6 lakh 55 thousand people die from heart disease in the United States alone. Continue reading →

Drug firm Alembic Pharmaceuticals on Friday said its arm, Alembic Global Holding SA, has received approval from the US health regulator for its generic Treprostinil injection used for the treatment of pulmonary arterial hypertension. "Alembic Global Holding SA has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Treprostinil injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), multiple-dose vials," Alembic Pharma said in a regulatory filing. The product is a generic version of United Therapeutics Corp Remodulin injection in the same strengths, it added Continue reading →

Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients Beyond Air recently initiated a pilot study using LungFitGO for at-home self-administration of up to 250 ppm NO to treat refractory NTM pulmonary disease in adult patients GARDEN CITY, N.Y., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc Continue reading →

Obesity is a major public health concern and associated with adverse cardiovascular conditions including dyslipidaemia, hypertension, type 2 diabetes and increased mortality. While weight management programs are generally centred on reduced calorie intake (through dieting) and increased energy expenditure (via exercise), maintaining weight loss overtime remains challenging. The glucagon-like peptide-1 analogue, semaglutide, is licensed for the management of type 2 diabetes and for reducing the risk of cardiovascular events in those with concomitant diabetes and cardiovascular disease. Continue reading →

This article was originally published here Diagn Cytopathol. Continue reading →

This article was originally published here Mikrobiyol Bul. 2021 Jan;55(1):91-98 Continue reading →